Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

BG Medicine Inc

Healthcare US BGMD

0.0001USD
0.00(0%)

Last update at 2026-06-03T20:00:00Z

Day Range

0.00010.0001
LowHigh

52 Week Range

0.00010.0001
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.00114M
  • Volume450
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.38600M
  • Revenue TTM1.57M
  • Revenue Per Share TTM0.16
  • Gross Profit TTM 1.06M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2015-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2015-12-31
Income before tax - - - - -5.30300M
Minority interest - - - - -
Net income - - - - -5.30300M
Selling general administrative - - - - 3.62M
Selling and marketing expenses - - - - 0.30M
Gross profit - - - - 1.06M
Reconciled depreciation - - - - -
Ebit - - - - -4.63000M
Ebitda - - - - -4.54300M
Depreciation and amortization 0.23M 0.24M 0.21M 0.17M 0.09M
Non operating income net other - - - - -0.51400M
Operating income - - - - -4.63000M
Other operating expenses - - - - 6.20M
Interest expense - - - - 0.16M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 0.16M
Total revenue - - - - 1.57M
Total operating expenses - - - - 5.69M
Cost of revenue - - - - 0.51M
Total other income expense net - - - - -0.51400M
Discontinued operations - - - - -
Net income from continuing ops - - - - -5.30300M
Net income applicable to common shares - - - - -6.95800M
Preferred stock and other adjustments - - - - 1.66M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2015-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2015-12-31
Total assets - - - - 2.13M
Intangible assets - - - - 0.08M
Earning assets - - - - -
Other current assets - - - - 0.10M
Total liab - - - - 4.11M
Total stockholder equity - - - - -1.97600M
Deferred long term liab - - - - 0.23M
Other current liab - - - - 0.37M
Common stock - - - - 0.01M
Capital stock - - - - -
Retained earnings - - - - -166.30500M
Other liab - - - - 0.34M
Good will - - - - -
Other assets - - - - 0.09M
Cash - - - - 1.52M
Cash and equivalents - - - - -
Total current liabilities - - - - 1.18M
Current deferred revenue - - - - 0.25M
Net debt - - - - -1.52500M
Short term debt - - - - 0.34M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - - - 164.32M
Property plant equipment - - - - 0.01M
Total current assets - - - - 1.95M
Long term investments - - - - -
Net tangible assets - - - - -2.05300M
Short term investments - - - - -
Net receivables - - - - 0.18M
Long term debt - - - - -
Inventory - - - - 0.14M
Accounts payable - - - - 0.56M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - 2.59M
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 0.09M
Deferred long term asset charges - - - - -
Non current assets total - - - - 0.18M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2011-12-31
Type yearly yearly yearly yearly yearly
Date 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2011-12-31
Investments - - - - -
Change to liabilities -0.16700M -1.44000M -2.03500M -0.15500M 0.39M
Total cashflows from investing activities 0.01M 0.01M -0.03200M -0.08500M -0.09300M
Net borrowings -2.48400M -4.48000M 2.53M 9.74M -0.10000M
Total cash from financing activities 1.06M 4.54M 10.29M 10.33M 36.51M
Change to operating activities 0.05M 0.11M 0.60M 0.28M -
Net income -5.30300M -8.06400M -15.84900M -23.76900M -17.58200M
Change in cash -2.59800M -3.62800M -5.03500M -11.08800M 21.45M
Begin period cash flow 4.12M 7.75M 12.79M 23.87M 2.42M
End period cash flow 1.52M 4.12M 7.75M 12.79M 23.87M
Total cash from operating activities -3.66700M -8.16700M -15.28800M -21.33300M -14.96600M
Issuance of capital stock - - - - -
Depreciation 0.09M 0.13M 0.17M 0.27M 0.42M
Other cashflows from investing activities 0.01M 0.01M 0.10M - -
Dividends paid -2.50000M - - - -
Change to inventory 0.26M 0.06M -0.01200M -0.23500M -
Change to account receivables -0.15800M 0.14M 0.08M -0.28000M 0.67M
Sale purchase of stock -0.45600M 9.02M 13.06M 0.59M 36.59M
Other cashflows from financing activities 2.00M -0.21900M -0.24000M 10.33M -0.82500M
Change to netincome 1.57M 0.89M 1.76M 2.53M 1.87M
Capital expenditures 0.00000M 0.00000M 0.13M 0.09M 0.09M
Change receivables -0.15800M 0.14M 0.08M -0.28000M 0.67M
Cash flows other operating 0.05M 0.11M 0.60M 0.31M -0.73300M
Exchange rate changes - - - - -
Cash and cash equivalents changes -2.59800M -3.62800M -5.03500M -11.08800M 21.45M
Change in working capital -0.02400M -1.12700M -1.36700M -0.38500M 0.20M
Stock based compensation 0.83M 0.67M 1.16M 2.36M 1.87M
Other non cash items 0.74M 0.22M 0.60M 0.19M -17.45400M
Free cash flow -3.66700M -8.16700M -15.42000M -21.41800M -15.05900M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BGMD
BG Medicine Inc		 - -% 0.0001 - - 0.0007 - 0.35 -0.108
ISRG
Intuitive Surgical Inc		 11.53 2.83% 418.82 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 - -% 201.48 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 4.49 4.57% 102.66 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 3.95 2.71% 149.56 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

BG Medicine, Inc., a diagnostics company, engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs in the United States, Europe, and internationally. It offers BGM Galectin-3 test, a novel diagnostic test that measures galectin-3 in blood plasma or serum; and CardioSCORE test that is designed to identify cardiovascular events, such as heart attack and stroke. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was incorporated in 2000 and is headquartered in Waltham, Massachusetts.

BG Medicine Inc

303 Wyman Street, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Dr. Paul R. Sohmer CEO, Pres & Director 1949
Mr. Stephen P. Hall CFO, Exec. VP & Treasurer 1951
Dr. Aram Adourian Chief Scientific Officer 1970
Dr. Paul R. Sohmer CEO, President & Director 1949
Mr. Stephen P. Hall CFO, Executive VP & Treasurer 1951
Dr. Aram Adourian Ph.D. Chief Scientific Officer 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions